Dossier assessment

Umeclidinium/vilanterol - Benefit assessment according to §35a Social Code Book V (dossier assessment)

Status
Status: Commission completed
Project no.
A14-22
Last updated

Report documents

  1. Extract of dossier assessment

    Umeclidinium/vilanterol - Benefit assessment according to §35a Social Code Book V (dossier assessment)

    published on
    Document type
    PDF document, 322 kB, EN, not accessible
  2. Dossier assessment

    Umeclidinium/vilanterol - Benefit assessment according to §35a Social Code Book V (dossier assessment)

    published on
    Document type
    PDF document, 549 kB, DE, not accessible

Press releases

No added benefit proven for umeclidinium/vilanterol in COPD

The scarce data available showed no advantages in moderate COPD severity and in few exacerbations / complete lack of data for higher severity grades with more exacerbations

Project details

Project no.
A14-22
Commission
Commission awarded on 14.07.2014 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Airways and respiratory system
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Addendum

    Addendum to Commission A14-22 (Umeclidinium/vilanterol)

    Project no.
    A14-45
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form